Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery

2 Jul 2025

Abstract excerpt

The efficacy of chimeric antigen receptor (CAR) T cell therapy in solid tumours is limited by immunosuppression and antigen heterogeneity1–3. To overcome these barriers, ‘armoured’ CAR T cells, which secrete proinflammatory cytokines, have been developed4. However, their clinical application has been limited because of toxicity related to peripheral expression of the armouring transgene5. Here, we have developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40604285
DOI: 10.1038/s41586-025-09212-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rewiring endogenous genes in CAR T cells for tumour-restricted payload deliveryPMID 40604285Read ↗

CRISPR engineering of armored CAR T cells enables tumor restricted payload delivery with enhanced efficacy and safetySemantic proximity Read ↗

CRISPR/Cas9 edited tumor-associated immune cells in cancer immunotherapySemantic proximity Read ↗

An <i>in vivo</i> CRISPR screen unveils top target genes to improve CAR-T cell efficacy in a solid tumor modelSemantic proximity Read ↗

Rational design of immune gene therapy combinations via <i>in vivo</i> CRISPR activation screen of tumor microenvironment modulatorsSemantic proximity Read ↗

Reprogramming human T cell function and specificity with non-viral genome targetingSemantic proximity Read ↗

Sense-and-respond payload delivery using a novel antigen-inducible promoter improves suboptimal CAR-T activationSemantic proximity Read ↗

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapySemantic proximity Read ↗

Personalized CRISPR Knock-In Cytokine Gene Therapy to Remodel the Tumor Microenvironment and Enhance CAR T Cell Therapy in Solid TumorsSemantic proximity Read ↗

A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptorSemantic proximity Read ↗

Using CRISPR to enhance T cell effector function for therapeutic applicationsSemantic proximity Read ↗

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editingSemantic proximity Read ↗

An optimised method for generation of murine CAR-T cells by CRISPR/Cas9Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.